Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Whitman

Showing results (151-160 of 169) with videos related to

Pageof 17
Sort By:
Leukemia|December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapySusan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
Blood|September 16, 2010
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Guido Marcucci, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signaturesJason H Mendler, Kati Maharry, Michael D Radmacher, et al.
Leukemia|June 15, 2013
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemiaK H Metzeler, K Maharry, J Kohlschmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemiaKrzysztof Mrózek, Guido Marcucci, Deedra Nicolet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B studyKlaus H Metzeler, Kati Maharry, Michael D Radmacher, et al.
Leukemia|May 11, 2013
Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AMLK M Bernot, R F Siebenaler, S P Whitman, et al.
Blood|July 27, 2010
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySusan P Whitman, Kati Maharry, Michael D Radmacher, et al.
Leukemia|March 22, 2014
Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8Heiko Becker, Kati Maharry, Krzysztof Mrózek, et al.
Blood|October 27, 2012
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemiaChristopher J Hickey, Sebastian Schwind, Hanna S Radomska, et al.
Pageof 17

Showing results (151-160 of 169) with videos related to

Sort By:
Pageof 17
Leukemia|December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapySusan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
Blood|September 16, 2010
BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySebastian Schwind, Guido Marcucci, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signaturesJason H Mendler, Kati Maharry, Michael D Radmacher, et al.
Leukemia|June 15, 2013
A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemiaK H Metzeler, K Maharry, J Kohlschmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemiaKrzysztof Mrózek, Guido Marcucci, Deedra Nicolet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B studyKlaus H Metzeler, Kati Maharry, Michael D Radmacher, et al.
Leukemia|May 11, 2013
Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AMLK M Bernot, R F Siebenaler, S P Whitman, et al.
Blood|July 27, 2010
FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySusan P Whitman, Kati Maharry, Michael D Radmacher, et al.
Leukemia|March 22, 2014
Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8Heiko Becker, Kati Maharry, Krzysztof Mrózek, et al.
Blood|October 27, 2012
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemiaChristopher J Hickey, Sebastian Schwind, Hanna S Radomska, et al.
Pageof 17